Nasdaq Edges Higher, Continuing Climb

[ad_1] The Nasdaq Composite climbed for a third consecutive day as shares of Nvidia, Amazon.com and Google parent Alphabet advanced. The tech-heavy index added 0.1%, leaving it down 1% in…

Illumina to divest cancer test maker Grail after antitrust battles

[ad_1] Rafael Henrique | Lightrocket | Getty Images Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and…

Illumina to Divest Itself of Cancer-Test Maker Grail

[ad_1] Updated Dec. 17, 2023 8:16 pm ET Gene-sequencing company Illumina said Sunday it will divest itself of cancer blood test maker Grail, following Illumina’s loss in its legal battle…

Court Sides With FTC Finding Illumina-Grail Deal Anticompetitive 

[ad_1] A federal appeals court said the U.S. government was right to challenge Illumina’s purchase of cancer-test developer Grail, but still sent the case back to the Federal Trade Commission…

Illumina Links Grail Divestiture to Losing European Or U.S. Appeals

[ad_1] by Alex Philippidis Illumina responded Friday to the European Commission (EC)’s order to divest itself of cancer blood test developer Grail by saying it will comply should it lose…

Carl Icahn says new Illumina CEO has his ‘full support’ months after proxy fight

[ad_1] Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016. David A. Grogan | CNBC Carl Icahn on Thursday expressed his support for Illumina‘s new CEO…

Illumina’s Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer

[ad_1] SAN DIEGO, Sept. 5, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has appointed…

Illumina names new CEO months after Icahn proxy fight over Grail deal

[ad_1] A building on the campus at the world headquarters of Illumina is shown in San Diego, California, Sept. 1, 2021. Mike Blake | Reuters Illumina‘s board on Tuesday named…

SEC investigating Illumina over acquisition of cancer test developer Grail

[ad_1] A building on the campus at the world headquarters of Illumina is shown in San Diego, California, Sept. 1, 2021. Mike Blake | Reuters The U.S. Securities and Exchange…